medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2004, Number 4

Next >>

Acta Ortop Mex 2004; 18 (4)

Total hip arthroplasty and venous thromboembolism disease

Figueroa-Gama RA, Mérida-Herrera E

Language: Spanish
References: 17
Page: 129-133
PDF size: 46.80 Kb.


ABSTRACT

A multicentric investigation was practiced in fourteen different medical centers in the country (161 cases) in total hip arthroplasty (THA) patients with high risk for developing a venous thromboembolism disease (VTD). No one of them has hematologic pathologies or tumoral processes. All of them took 40 mg subcutaneous of Low -Molecular- Weight-Heparins before surgery process up to at least ten days after it. All these patients had one to five risk factors of VTD. Tobacco was dominant in men and fatness and hypertension in females. 80% of these cases, hemoglobin was more than 10 mg and hematocrit more than 30. Three cases with bleeding more than normal average of THA, but with no adverse reactions. Nobody presented subsequent clinical data of VTD and this is why it’s better previously know all risk factors of each patients and face them . Even better to avoid fearing bleeding and use anti coagulants before any bad experience.


REFERENCES

  1. Anderson FA, Wheeler HB, Goldberg RJ, Hosner DW, Forcier A: The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152(8): 1660-1664.

  2. Boda Z, Laszlo P, Retjo L, Tornai I, et al: Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy. Thromb Haemost 1996; 76(1): 128.

  3. Caprini JA, Arcelus JI, Hoffman K, Mattern T, Laubach M, Size GP, Traverso CI, Coats R: Prevention of venous thromboembolisms in North America: results of a survey among general surgeons. J Vasc Surg 1994; 20: 751-758.

  4. Clagett GP, Anderson FA Jr, Geerts W, Heit WA, Knudson M, Lieberman HR, Merli GJ, Wheeler HB: Prevention of Venous Thromboembolism. Chest 1998; 114(5 Suppl): 531S-560S.

  5. Clagett GP, Anderson FE Jr, Heit J, Levine MN, Wheeler HB: Prevention of venous thromboembolism. Chest 1995; 108 Suppl: 312S-334S.

  6. Estado actual de la profilaxis primaria de la enfermedad tromboembólica venosa. Valoración del riesgo y recomendaciones en las áreas médicas y quirúrgicas. Revista Iberoamericana de Trombosis y Hemostasia 1999; 12(2): 195.

  7. Gardlund B: Randomized, controlled trial of low-dose heparin for the prevention of fatal pulmonary embolism in patients with infections diseases. The Heparin Prophylaxis Study Group Lancet 1996; 347(9012): 1357-1361.

  8. Green D, Lee MY, Lim AC, et al: Preventions of thromboembolism after spinal cord injury using low-molecular-eight heparin. Ann Intern Med 1990; 113(8): 571-574.

  9. Monreal M, Raventos A, Lerma R, et al: Pulmonary embolism in patients with upper extremity DVT associated to venous central lines. A prospective study. Throm Haemost 1994; 72(4): 548-550.

  10. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T: A prospective study of the incidence of deep-vein thrombosis within a defined urban populations. J Intern Med 1992; 232(2): 155-160.

  11. Planes A, Vochelle N, Fagola M, Bellaud M: Dosificación, una vez al día de enoxaparina en la prevención de la trombosis venosa profunda después del reemplazo total de cadera. Comunicación personal, XVIII Congreso Internacional de Tromboembolismo y Hemostasia, París, Julio 2001.

  12. Prevention of venous thromboembolism; international consensus statements. Int Angiol 1997; 16: 3-38.

  13. Quinta Conferencia de Consenso de la ACCP sobre tratamiento antitrombótico. Chest 1998; 114: 489S-510S.

  14. Quinta Conferencia de Consenso de la ACCP sobre tratamiento antitrombótico. Chest 1998; 114: 531S-560S.

  15. Samana M, Combe S. Prevención de la enfermedad tromboembólica en Cirugía General. Br J Surg 1988; 75: 128-131.

  16. Sigler S, Tomero T, Meillon L, Gutiérrez L, Aguirre-García J, Esparza C. Tromboembolia pulmonar en autopsias en un período de 10 años. Rev Med IMSS (Mex) 1996; 34(1): 7-11.

  17. Simoneau G, Charbonier B, Decousus H. Heparina de bajo peso molecular por vía subcutánea comparada con heparina no fraccionada por vía intravenosa continua, en el tratamiento de la trombosis venosa profunda proximal. Arch Intern Med 1993; 153: 1541-1546.




2020     |     www.medigraphic.com